Original Research
Published on 09 Feb 2026
Cost-effectiveness of ramucirumab plus paclitaxel as maintenance therapy for patients with advanced HER2-negative gastric or gastroesophageal junction cancer
in Gastrointestinal Cancers: Gastric and Esophageal Cancers
- 385 views